- JD Health reported a first-half revenue of 35.29 billion yuan, surpassing the estimated 33.97 billion yuan.
- The company achieved a net income of 2.60 billion yuan.
- JD Health’s earnings per share (EPS) were recorded at 81 RMB cents.
- The non-IFRS profit was 3.57 billion yuan.
- Research and development expenses amounted to 736.4 million yuan, slightly above the estimate of 735.8 million yuan.
- Analyst recommendations include 20 “buy” ratings, 5 “hold” ratings, and 1 “sell” rating.
“`
A look at JD Health International Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
JD Health International Inc. holds a promising long-term outlook based on its Smartkarma Smart Scores analysis. With a solid rating of 5 in Growth and Momentum, the company is poised for significant expansion and upward market momentum in the future. This indicates a strong potential for growth and positive performance in the coming years.
While the company scores lower in Dividend at 1, it makes up for this with a balanced rating of 3 in Value and a robust score of 4 in Resilience. This suggests that JD Health International is well-positioned to weather market challenges and maintain stable operations over the long term. With a focus on retailing Chinese and Western medicines, nutrition products, and health care items across China, JD Health International demonstrates a diverse product offering aimed at catering to the health needs of consumers.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
